BioNTech SE has reached a settlement with the University of Pennsylvania on December 23, 2024, agreeing to pay up to $467 million regarding royalties for the COVID-19 vaccine partnership with Pfizer from 2020-2023, while denying any liability. Additionally, Pfizer will reimburse BioNTech up to $170 million of these claimed royalties.